Article info
PDFResearch ethics
Paper
Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study
- Correspondence to Aafreen Saiyed, Department of Pharmacology and Therapeutics, Seth GS Medical College, KEM Hospital, Parel, Mumbai, Maharashtra 400012, India; aafrinsaiyed{at}yahoo.co.in
Citation
Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study
Publication history
- Received September 14, 2013
- Revised February 14, 2014
- Accepted May 5, 2014
- First published June 25, 2014.
Online issue publication
June 29, 2021
Article Versions
- Previous version (29 June 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Failure to adhere to study plans is the most common research error among US investigators
- Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators
- Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold
- Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981–2014: a retrospective observational study
- Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
- Streamlining the Clinical Research Enterprise
- Blood product use for radiological/nuclear trauma: product development and US regulatory considerations
- Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis
- Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
- The FDA, Juno Therapeutics, and the ethical imperative of transparency